Nephrology · Oncology · Cardiology · 1 h ago
Cardiovascular–kidney–metabolic syndrome linked to cancer in emerging evidence
A Nature Reviews Nephrology article discusses epidemiological and multiomics evidence linking cardiovascular–kidney–metabolic syndrome with cancer. The authors suggest potential for integrated screening and prevention, but the available preview provides no sample sizes, effect estimates or evidence of clinical benefit.
- Epidemiological and multiomics evidence suggests links between CKM syndrome and cancer.
- Shared inflammatory, metabolic and immune pathways may inform prevention research.
- Available preview provides no quantitative findings or demonstrated screening benefit.
An article by P. Hatamizadeh and K. D. Jhaveri in Nature Reviews Nephrology discusses evidence linking cardiovascular–kidney–metabolic (CKM) syndrome with cancer. CKM syndrome describes the close relationships among cardiovascular, kidney and metabolic health. Drawing on epidemiological and multiomics research, the authors suggest that shared inflammatory, metabolic and immune pathways could offer targets for integrated screening and prevention strategies. However, these strategies are presented as a possibility for improving outcomes, not as established clinical interventions. The accessible subscription preview provides no sample sizes, quantitative risk estimates or intervention results, limiting assessment of the strength and clinical applicability of the evidence. It does not establish that changing cancer screening on the basis of CKM status improves outcomes. The authors declare no competing interests.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Nature Reviews Nephrology: Cardiovascular–kidney–metabolic syndrome and cancer ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.